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Abstract 
Hexamidine diisethionate (HEX D) has been used for its biocidal actions in 
topical preparations since the 1950s. Recent data also suggest that it plays a 
beneficial role in skin homeostasis. To date, the extent to which this compound 
penetrates the epidermis has not been reported nor how its topical delivery may be 
modulated. In the present work we set out to characterise the interaction of HEX D 
with the skin and to develop a range of simple formulations for topical targeting of 
the active. A further objective was to compare the skin penetration of HEX D with its 
corresponding dihydrochloride salt (HEX H) as the latter has more favourable 
physicochemical properties for skin uptake. Candidate vehicles were evaluated by in 
vitro Franz cell permeation studies using porcine skin. Initially, neat solvents were 
investigated and subsequently binary systems were examined. The solvents and 
chemical penetration enhancers investigated included glycerol, dimethyl isosorbide 
(DMI), isopropyl alcohol (IPA), 1,2-pentanol (1,2-PENT), polyethylene glycol 
(PEG) 200, propylene glycol (PG), propylene glycol monolaurate (PGML) and 
Transcutol®P (TC). Of a total of 30 binary solvent systems evaluated only 10 
delivered higher amounts of active into the skin compared with the neat solvents. In 
terms of topical efficacy, formulations containing PGML far surpassed all other 
solvents or binary combinations. More than 70% of HEX H was extracted from the 
skin following application in PG:PGML (50:50). Interestingly, the same vehicle 
effectively promoted skin penetration of HEX D but demonstrated significantly 
lower uptake into and through the skin (30%). The findings confirm the 
unpredictable nature of excipients on delivery of actives with reference to skin even 
where there are minor differences in molecular structures. We also believe that they 
underline the ongoing necessity for fundamental studies on the interaction of topical 
excipients with the skin.  
Key words: Hexamidine, skin, formulation, solvents, chemical penetration 
enhancers 
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Introduction 
Hexamidine diisethionate (HEX D) has been used as a biocide in topical 
preparations since 1950 (Robin, 1978) but recent evidence indicates it may have also 
have a beneficial effect on skin homeostasis. It has been suggested that the inhibitory 
action of HEX on inflammatory proteases in skin may result in modulation of skin 
ageing processes (Kimball et al., 2012). Synthesis of sphingolipid, fatty acid and 
cholesterol was downregulated in human skin equivalent cell cultures following 
incubation with HEX D, as was fatty acid and cholesterol uptake; the efflux of 
cholesterol was also upregulated (Osborne et al., 2009; Jarrold et al., 2010a). In vivo 
studies conducted with an emollient containing HEX D and other ingredients have 
also shown improved skin barrier function compared with controls (Jarrold et al., 
2010b).  
Surprisingly the disposition of HEX D in skin has not been examined to date. 
In a recent publication (Parisi et al., 2015) we reported the preparation of the 
dihydrochloride salt (HEX H) as well as the characterisation of both molecules. The 
rationale for preparation of HEX H was based on its likely more favourable 
properties for topical delivery compared with HEX D. Effective skin penetration has 
been observed for molecules with low molecular weights (<500), low melting points 
and balanced lipophilic – hydrophilic properties (Hadgraft, 2004). Although HEX H 
was successfully prepared in the pure form, the melting point of the molecule was 
higher than that of HEX D. Thermal analysis indicated the melting points of HEX D 
and HEX H were 225°C and 266°C respectively. Log D values at pH 7.4 were -0.74 
for HEX D and -0.70 for HEX H respectively. The investigation of the 
physicochemical properties of HEX D and HEX H also included determination of 
UV absorption spectra, pH in aqueous solution, development of appropriate HPLC 
analytical methods as well as evaluation of solubility and stability in a broad range of 
solvents and selected binary solvent systems. Following on from these pre-
formulation studies, the aim of the present work was to identify and develop simple 
formulations to deliver both HEX D and HEX H to the skin.  
Because of the excellent barrier properties of the skin, the bioavailability of 
topically applied active ingredients is generally low. Chemical penetration enhancers 
(CPEs) are often included in pharmaceutical and cosmetic formulations to improve 
delivery of actives. Although the precise mechanism of action of most CPEs remains 
poorly understood, two major effects may be observed when they penetrate the 
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stratum corneum (Hadgraft, 1999). Some CPEs, usually simple solvent type 
molecules, can alter the skin permeability by increasing the solubility of the 
permeant in the stratum corneum. Other enhancers may, instead, increase the 
diffusion coefficient of the permeant by intercalating into the highly organised lipid 
domain of the stratum corneum and disrupting its packing, thus making it more fluid 
(Lane, 2013). Finally, a synergistic effect may be obtained by combining in the same 
formulation chemical penetration enhancers having different mechanisms of action 
(Hadgraft, 1999).  
Single solvent systems were selected as the starting point for the development 
and evaluation of optimal formulations for the topical delivery of HEX D and HEX 
H. Based on the solubility data for HEX D and HEX H in 19 solvents studied in our 
previous work (Parisi et al., 2015), propylene glycol (PG), glycerol and PEG 200 
were identified as suitable candidate vehicles. Conducting in-vitro skin permeation 
studies using diffusion cells is by far the most accepted method used to investigate 
and screen a series of topical formulations in order to select those which perform 
better in terms of active ingredient release to the desired target (Franz, 1975; 
Organisation for Economic Cooperation and Development, 2004; Hirata et al., 
2013). Permeation studies, however, only allow the quantification of the amount of 
active which cross the skin barrier. Therefore for this study they are coupled with 
mass balance studies which provide information on both the amount of active which 
remains on the skin surface and that which is delivered inside the skin (Tsai et al., 
1992; OECD, 2004; Oliveira et al., 2012). A range of binary systems which 
combined the single solvents with other CPEs were subsequently prepared and 
examined. The choice of CPE was based on their miscibility with PG, glycerol and 
PEG 200 as well as reports in the literature detailing their applications in topical and 
transdermal delivery (Lane, 2013).  
 
2. Materials and Methods 
2.1 Materials 
HEX D (Laboratoires Sérobiologiques, France) was a kind gift from Procter & 
Gamble (U.K.), while HEX H was synthesized and purified in-house. Porcine ears 
were obtained from a local abattoir. Propylene glycol (PG), polyethylene glycol 200 
(PEG 200) and HPLC grade isopropyl alcohol (IPA) were supplied by Fisher 
Scientific (U.K.). HPLC grade water, HPLC grade methanol and glycerol were 
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provided by Sigma-Aldrich (U.K.). Dimethyl sulfoxide (DMSO) was supplied by 
VWR International (U.K.). Lauroglycol™ 90 (Propylene glycol monolaurate, 
PGML) and Transcutol® P (TC) were received as kind donations from Gattefossé 
(France). 1,2-pentanediol (1,2-PENT) was provided by Surfachem Group (U.K.). 
Dimethyl isosorbide Arlasolve® (DMI) was supplied by Croda International (U.K.). 
Phosphate buffered saline (PBS) (pH = 7.3 ± 0.2 at 25°C) was prepared using 
Dulbecco A tablets (Oxoid, U.K.). 
 
2.2 Methods 
2.2.1 Preparation of HEX D and HEX H formulations and solubility determination 
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HEX D and HEX H solutions (0.1% w/v) were prepared by placing 5 mg of active 
ingredient in a screw top glass test tube containing a Teflon®-coated magnetic stir 
bar. The concentration selected is the amount which is currently approved for use in 
personal care products (Cosmetic Ingredient Review Expert Panel, 2007). Solutions 
were allowed to stir and equilibrate overnight at 32 ± 1°C. If no visible excess of 
active ingredient was found, the solution was used without further processing. If a 
saturated solution with a visible excess of drug was obtained, a sample was 
withdrawn and centrifuged at 13200 rpm for 15 min at 32 ± 1°C in an Eppendorf 
5415R centrifuge (Eppendorf, Germany). The supernatant was then used without 
further processing. Finally, the concentrations of HEX D and HEX H in all solutions 
were determined by HPLC (Parisi et al., 2015). In vitro permeation and mass balance 
studies were performed with the following single solvent systems: 0.1% w/v HEX D 
in PG, glycerol and PEG 200 and 0.1% w/v HEX H in PG, glycerol and PEG 200. In 
vitro permeation and mass balance studies were performed with the following binary 
solvent systems: 0.1% w/v HEX D in PG:TC (50:50), glycerol:TC (50:50), PEG 
200:TC (50:50), PG:DMI (50:50), glycerol:DMI (50:50), PG:1,2-PENT (50:50), 
glycerol:1,2-PENT (50:50), PEG 200:1,2-PENT (50:50), PG:IPA (50:50), 
glycerol:IPA (50:50), PEG 200:IPA (50:50) and HEX D at saturation solubility in 
PEG 200:DMI (50:50), PG:PGML (50:50), glycerol:PGML (50:50) and PEG 
200:PGML (50:50). For HEX H, the same binary solvent systems as for HEX D 
were used, but the content of HEX H was 0.1% w/v. The solubility of HEX D and 
HEX H in the neat solvents was reported in our previous publication and for the 
binary systems solubility was determined in the same manner (Parisi et al., 2015). 
Briefly, an excess amount of active was added to each solvent in a glass test tube 
containing a Teflon®-coated magnetic stir bar. The test tube was sealed with 
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Parafilm® and placed in a SUB 28 thermostatically controlled water bath (Grant 
Instruments, U.K.) equipped with a Telesystem HP 15 submersible magnetic stirrer 
(Variomag®-USA, U.S.A.). The system was allowed to stir and equilibrate for 48 h at 
32 ± 1°C to obtain a saturated solution. After the 48 h period, a sample was 
withdrawn from the test tube and centrifuged at 13200 rpm for 15 min at 32 ± 1°C in 
an Eppendorf 5415R centrifuge (Eppendorf, Germany). Following sample dilution 
the concentration of the active was determined by HPLC.  
 
2.2.2. In vitro permeation studies  
All permeation studies were conducted using glass vertical Franz diffusion 
cells and porcine ear skin and followed procedures reported previously (Caon et al., 
2010; Oliveira et al., 2012). Full thickness skin tissue was used for all experiments. 
The Franz cell experiments were conducted in a SUB 28 (Grant Instruments, U.K.) 
temperature controlled water bath equipped with a Telesystem HP 15 (Variomag®-
USA, U.S.A.) submersible magnetic stirrer. The skin temperature was equilibrated to 
32 ± 1°C. 250 μL of the test solution were then applied to the donor compartment 
which was not occluded. Samples of receptor solution were collected at 0, 6, 12, 20, 
24, 28, 32, 45 and 48 h. The sample volume was 100 µL and, after removal an equal 
volume of fresh PBS at 32 ± 1°C was added to the receptor compartment. Finally, 
the HEX D and HEX H concentration in all the samples was determined by HPLC 
(Parisi et al., 2015).  
 
2.2.3 Mass balance studies and validation  
At the end of the 48 h permeation studies, the receptor solution was removed 
from the Franz cells. The donor solution was then withdrawn from each donor 
compartment and placed in a 10 mL volumetric flask. For hydrophilic solvents 
HPLC grade water was used for dilution and for hydrophobic solvents DMSO was 
used. After removing the donor solution, the skin surface was washed twice (each 
wash consisting of 5 solvent rinses) with HPLC grade water in the case of 
hydrophilic donor solutions and with DMSO for hydrophobic donor solutions. The 
Franz diffusion cells were then disassembled, the skin membranes were placed in 
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centrifuge microtubes and extracted with DMSO:methanol (50:50) on a rotor for 24 
h at 32 ± 1°C. Two cycles of sonication (15 min) and centrifugation at 13200 rpm 
(15 min) were performed in order to complete the extraction. The HEX D and HEX 
H concentrations in all the diluted donor solutions, washing samples and extraction 
samples were determined by HPLC (Parisi et al., 2015). The total active ingredient 
recovery (%) was then used as an indicator of the reliability of the procedure and 
values within the range from 80% to 120% were considered acceptable (OECD, 
2011).  
 The mass balance methods were validated using a 0.1% w/v solution of HEX 
D in PG for hydrophilic vehicles and a 0.1% w/v solution of HEX H in PG:PGML 
for hydrophobic vehicles. The Franz diffusion cells were assembled as for typical 
permeation studies but receptor compartments contained no PBS. Following 
equilibration to the experimental temperature (32 ± 1°C), 250 µL of donor solution 
were applied to the skin surface for 6 h. At the end of the 6 h period, the PG donor 
solution was withdrawn and placed in a 10 mL volumetric flask and diluted with 
HPLC grade water. The solution of HEX H in PG:PGML was diluted with DMSO. 
After removing the donor solution, the skin surface was washed 5 times with HPLC 
grade water for the PG donor solution, and with DMSO for the PG:PGML solution. 
The Franz diffusion cells were then disassembled, the skin membranes were placed 
in centrifuge microtubes and extracted as described for the mass balance studies. 
HEX D and HEX H concentrations in all the diluted donor solution, washing samples 
and extraction samples were determined by HPLC (Parisi et al., 2015); validation 
required total recovery values of between 95% and 105%.  
 
2.2.4 Data treatment and statistical analysis 
The data analysis was performed using Microsoft® Excel 2010 (Microsoft 
Corporation, U.S.A.) and OriginPro® 9.1.0 (OriginLab Corporation, U.S.A.). The 
data points falling between the LOQ and the LOD were not excluded and were used 
in the same manner as those above the LOQ (Keizer et al., 2015). The data below the 
LOD were instead excluded. As a result, when all the observations constituting a 
sample were below the LOD, this was reported as not detected (ND). However, when 
the observations constituting a sample were both above and below the LOD, the 
latter were statistically estimated in order to be able to calculate meaningful 
descriptive statistics, such as the sample arithmetic mean, standard deviation (SD) 
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and standard error of the mean (SEM). The results are presented as mean ± SD or 
mean ± SEM. The normality of the data was assessed using the Shapiro-Wilk and 
Kolmogorov-Smirnov tests. Parametric statistical tests (one-way ANOVA and 
independent-samples t-test) were used to compare means and investigate statistical 
differences for normally distributed data. When the data showed a non-normal 
distribution, the Kruskal-Wallis test and the Mann-Whitney u-test (non-parametric 
tests) were used as alternatives for the one-way ANOVA and independent-samples t-
test, respectively. The one-sample t-test was used to compare the mean of a normal 
sample with a ND sample whose mean was considered to be zero. Finally, a 
probability of p < 0.05 was considered statistically significant. 
 
3. Results and Discussion 
3.1 Mass balance method validation 
The results of the validation of the mass balance methods for the solutions of 
HEX D in PG and HEX H in PG:PGML are shown in Figure 1.  
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HEX D and HEX H were largely recovered from the skin surface in the 
residual donor solutions plus washings (Figure 1). The recovery of the active 
ingredients from the residual donor solutions accounted for more than 90% of the 
applied doses, while the first washing consisted of between 3% and 7% of the dose. 
No HEX D and HEX H were detected in washing steps 3, 4 and 5 for the solution of 
HEX D in PG and the solution of HEX H in PG:PGML. As a result, only two 
washing steps were performed in all subsequent mass balance studies. Following 
skin extraction, small quantities of active were recovered for the solutions of HEX D 
in PG and HEX H in PG:PGML (0.70% and 1.39% of the applied doses, 
respectively). The efficiency of the mass balance methods was validated by the total 
recovery values which were within the range of 95% to 105%. 
 
 
 
 
Figure 1 Residual donor solution, washing (W), extraction and total recovery of HEX D and 
HEX H for HEX D in PG and HEX H in PG:PGML (4≤n≤5; mean ± SD) 
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3.2 In vitro permeation and mass balance studies using single solvent systems 
No permeation was observed for solutions of HEX D in PG, glycerol and 
PEG 200. The results of the mass balance studies are presented in Table 1. More than 
90% of the applied HEX D was recovered from the skin surface. In addition, the skin 
surface recovery for each vehicle was not statistically different from the respective 
total recovery (one-way ANOVA, p > 0.05) which ranged from 91.36% for the PEG 
200 solution to 93.10% for the glycerol solution. Values for skin surface and total 
recovery were statistically higher than for skin extraction (one-way ANOVA, p < 
0.001). Less than 1% of the applied HEX D was delivered into the skin. This is not 
surprising considering that the molecular weight, the log Do/w at pH = 7.4 and the 
melting point of HEX D are not ideal for topical drug delivery (Parisi et al., 2015). In 
addition, although PG, glycerol and PEG 200 were specifically selected because of 
the high solubility of HEX D in these solvents, this may have limited HEX D 
distribution into the stratum corneum. No significant differences were found between 
individual solvents for values of active extracted from skin (one-way ANOVA, p > 
0.05).  
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Table 1 Skin surface, skin extraction and total HEX D recovery (%) for single and binary 
solvent systems following application to porcine skin for 48 h. The amounts (µg) of HEX D 
extracted from the skin are also shown in brackets. (4≤n≤5; mean ± SD) 
Vehicle Skin surface Skin extraction Total recovery 
PG 91.95 ± 6.16 0.72 ± 0.09 (1.77 ± 0.22) 92.66 ± 6.13 
Glycerol 92.23 ± 11.99 0.87 ± 0.18 (1.95 ± 0.41) 93.10 ± 11.97 
PEG 200 90.38 ± 1.48 0.99 ± 0.28 (2.48 ± 0.70) 91.36 ± 1.21 
PG:TC 89.95 ± 2.10 0.46 ± 0.02 (1.20 ± 0.05)† 90.40 ± 2.10 
Glycerol:TC 86.62 ± 1.25 0.46 ± 0.06 (1.30 ± 0.16)† 87.08 ± 1.26 
PEG 200:TC 88.86 ± 1.52 0.64 ± 0.05 (1.63 ± 0.13) 89.49 ± 1.48 
PG:DMI 106.97 ± 2.00 ND† 106.97 ± 2.00 
Glycerol:DMI 100.21 ± 5.25 ND† 100.21 ± 5.25 
PEG 200:DMI 90.94 ± 0.74 1.03 ± 0.41 (1.42 ± 0.57)† 91.97 ± 0.73 
PG:1,2-PENT 89.11 ± 5.09 1.01 ± 0.16 (2.38 ± 0.37)* 90.13 ± 4.96 
Glycerol:1,2-PENT 93.69 ± 6.30 1.04 ± 0.18 (2.42 ± 0.41) 94.73 ± 6.26 
PEG 200:1,2-PENT 85.77 ± 5.08 0.99 ± 0.18 (2.37 ± 0.44) 86.76 ± 5.07 
PG:IPA 87.07 ± 5.13 3.48 ± 1.69 (8.48 ± 4.14)* 90.55 ± 3.68 
Glycerol:IPA 86.20 ± 1.10 2.98 ± 0.96 (7.37 ± 2.37)* 89.18 ± 2.02 
PEG 200:IPA 88.50 ± 4.71 1.70 ± 0.59 (4.23 ± 1.48)* 90.19 ± 4.60 
*Binary solvent system which delivered significantly higher amount of active compared with neat solvent 
†Binary solvent system which delivered significantly lower amount of active compared with neat solvent 
  
Similarly for HEX H, no permeation was observed after the 48 h in-vitro permeation 
studies for PG, glycerol and PEG 200 solutions (Table 2).   
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Table 2 Skin surface, skin extraction and total HEX H recovery (%) for single and binary 
solvent systems following application to porcine skin for 48 h. The amounts (µg) of HEX H 
extracted from the skin are also shown in brackets. (3≤n≤5; mean ± SD) 
Vehicle Skin surface Skin extraction Total recovery 
PG 92.77 ± 4.23  1.51 ± 0.91 (3.63 ± 2.18) 94.29 ± 3.36 
Glycerol 99.10 ± 11.62  1.03 ± 0.25 (2.39 ± 0.57) 100.13 ± 11.49 
PEG 200 86.04 ± 1.67  2.18 ± 0.62 (4.48 ± 1.27) 88.23 ± 1.53 
PG:TC 94.24 ± 2.73 0.71 ± 0.10 (1.26 ± 0.19)† 94.95 ± 2.82 
Glycerol:TC 98.46 ± 5.50 0.46 ± 0.15 (0.94 ± 0.31† 98.92 ± 5.40 
PEG 200:TC 97.62 ± 2.21 0.57 ± 0.03 (1.20 ± 0.07)† 98.19 ± 2.19 
PG:DMI 94.53 ± 2.03 0.53 ± 0.21 (1.36 ± 0.55)† 95.06 ± 2.20 
Glycerol:DMI 92.79 ± 4.02 0.40 ± 0.27 (1.02 ± 0.69)† 93.20 ± 4.22 
PEG 200:DMI 96.13 ± 1.97 0.85 ± 0.04 (2.01 ± 0.09) 96.98 ± 1.99 
PG:1,2-PENT 91.17 ± 3.82 1.04 ± 0.24 (2.07 ± 0.47)† 92.21 ± 3.81 
Glycerol:1,2-PENT 94.27 ± 3.92 0.79 ± 0.08 (1.78 ± 0.18) 95.06 ± 3.91 
PEG 200:1,2-PENT 95.89 ± 2.47 1.14 ± 0.25 (2.30 ± 0.50)† 97.03 ± 2.23 
PG:IPA 97.52 ± 4.34 1.12 ± 0.13 (2.45 ± 0.28) 98.65 ± 4.29 
Glycerol:IPA 101.00 ± 4.20 1.46 ± 0.29 (3.08 ± 0.60) 102.47 ± 4.40 
PEG 200:IPA 102.62 ± 3.34 1.37 ± 0.18 (2.96 ± 0.39)† 103.98 ± 3.44 
†Binary solvent system which delivered significantly lower amount of active compared with neat solvent 
 
More than 85% of the applied HEX H remained on the skin surface, while the 
skin extraction recoveries ranged from 1.03% for glycerol solution to 2.18% for PEG 
200.  Values for skin surface and total recovery were not significantly different (one-
way ANOVA, p > 0.05); but were statistically higher than the respective skin 
extraction recovery values (one-way ANOVA, p < 0.001). No statistical differences 
were found (one-way ANOVA, p > 0.05) between amounts of active extracted from 
the skin for the individual formulations. The conversion of HEX D to HEX H does 
appear to impact on topical delivery, subject to the vehicle selected. Statistically 
higher amounts of HEX H were extracted from the skin for the PG and PEG 200 
vehicles compared with the corresponding HEX D solutions (Mann-Whitney u-test, p 
< 0.01; independent-samples t-test, p < 0.05). However, no significant differences 
were found between the amounts of the two actives extracted from the skin for the 
glycerol vehicle (independent-samples t-test, p > 0.05). 
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3.3 In-vitro permeation and mass balance studies using binary solvent systems 
3.3.1 Binary systems of PG, glycerol and PEG 200 with TC 
Binary solvent systems consisting of PG, glycerol and PEG 200 in combination 
with TC did not promote HEX D delivery through the skin. No active was found in 
the receptor compartment following the in-vitro permeation studies with solutions of 
HEX D in PG:TC, glycerol:TC  and PEG 200:TC (Table 1). Less than 0.65% of the 
applied HEX D was delivered into skin by binary combinations of PG, glycerol or 
PEG 200 with TC (Table 1). Unsurprisingly, there were no significant differences 
between the skin surface and the total recoveries (one-way ANOVA, p > 0.05) which 
are significantly higher than the corresponding skin extraction recoveries (one-way 
ANOVA, p < 0.001). Although the overall topical delivery of HEX D was poor, the 
amount of active extracted from the skin for PEG 200:TC was significantly higher 
than values for PG:TC and glycerol:TC  (one-way ANOVA, p < 0.01).  
As for HEX D most of the HEX H remained on the skin surface (Table 2) and 
corresponding recovery values are not statistically different from those for total 
recovery (one-way ANOVA, p > 0.05). The amount of HEX H extracted from skin 
was less than 0.75% of the applied dose for all solutions and significantly lower than 
the respective skin surface and total recoveries (one-way ANOVA, p < 0.001). There 
are no statistical differences in amounts of HEX H delivered into skin for the binary 
systems (one-way ANOVA, p > 0.05). In contrast to what was observed for the 
single solvent systems, the use of the dihydrochloride salt in place of the 
diisethionate did not improve the topical delivery of HEX. The amounts of HEX H 
extracted from the skin for glycerol:TC and PEG 200:TC were, instead, significantly 
lower than amounts of HEX D extracted from skin for the same vehicles 
(independent-samples t-test, p < 0.05 and p < 0.001, respectively). No differences 
were found between amounts of HEX H and the HEX D extracted for PG:TC 
(independent-samples t-test, p > 0.05). A possible explanation for this is that HEX H 
is 5.4-fold more soluble in TC than HEX D (2.00 and 0.37 mg/mL respectively). 
Therefore, the higher solubility should result in a lower thermodynamic activity of 
HEX H in the binary solvent systems compared with HEX D. Ultimately this would 
result in a reduced driving force for HEX H into the skin despite the more favourable 
physicochemical properties of HEX H for topical delivery compared with HEX D.  
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We hypothesised that the use of TC in combination with PG, glycerol and PEG 
200 might enhance the topical delivery of HEX D and HEX H in comparison to 
delivery in single solvents. Harrison et al. (1996) and Puglia and Bonina (2008) 
reported increased fluxes across human skin for 4-cyanophenol and atenolol, 
respectively, and suggested that this reflected the ability of TC to facilitate 
solubilisation of active in the skin. However, the single solvent systems of HEX D 
and HEX H clearly performed better than the binary solvent systems. PG delivered 
significantly higher amounts of HEX D or HEX H into the skin compared with the 
corresponding solutions in PG:TC (Mann-Whitney u-test, p < 0.01 and p < 0.05, 
respectively). A similar trend was observed for solutions of HEX D and HEX H in 
glycerol (independent-samples t-test, p < 0.05 and p < 0.01, respectively) and for 
HEX H in PEG 200 (independent-samples t-test, p < 0.05). Finally, the amount of 
HEX D delivered from PEG 200 was not statistically different from that delivered by 
the PEG 200:TC vehicle (independent-samples t-test, p = 0.052). The excellent 
solubilising properties and the safety of TC are two of the main reasons behind its 
long-standing use in pharmaceutical and cosmetic products (Sullivan Jr. et al., 2014). 
TC is also widely used for its enhancing action on the transdermal delivery of active 
ingredients and for its ability to promote topical delivery via formation of 
intracutaneous depots (Osborne, 2011). This last effect was particularly appealing 
considering that the aim of this work was the topical delivery of HEX D and HEX H. 
However, as noted by Osborne (2011) it is difficult to make predictions of the 
efficacy of TC in enhancing the permeation of active ingredients. The precise 
mechanism of action of this compound where it does function as a CPE is still not 
fully understood. We have also recently reported the superior penetration of TC 
compared with PG and butylene glycol in human skin in vitro where saturated 
solutions of a different model active were investigated (Hadgraft and Lane, 2016).   
 
3.3.2 Binary systems of PG, glycerol and PEG 200 with DMI  
 Permeation was not observed for HEX D in PG:DMI, glycerol:DMI and the 
saturated solution of HEX D in PEG 200:DMI. No HEX D was detected inside the 
skin for PG:DMI and glycerol:DMI, while ~ 1% of the applied dose was delivered 
from the saturated solution of HEX D in PEG 200:DMI (Table 1). The measured 
saturated solubility of HEX D in this vehicle at 32°C was 0.55±0.04 mg/mL (n=3). 
Thus the amount in the skin corresponded to 1.42 ± 0.57 μg of HEX D, a statistically 
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higher amount than the PG:DMI and glycerol:DMI vehicles (one-sample t-test, p < 
0.01). Skin surface recovery of HEX D from the saturated PEG 200:DMI solution 
was not significantly different from the total recovery (one-way ANOVA, p > 0.05). 
As for HEX D, no permeation was observed for solutions of HEX H in PG:DMI, 
glycerol:DMI and PEG 200:DMI (Table 2). 
In contrast to HEX D, binary solvent systems of DMI with PG, glycerol and 
PEG 200 delivered HEX H into the skin although the amounts were low, with less 
than 0.90% of the applied amount recovered (Table 2). The PG:DMI and the PEG 
200:DMI systems delivered statistically similar amounts of HEX H into the skin 
(independent-samples t-test, p > 0.05). However, while no significant difference was 
found between the former and the glycerol:DMI vehicle (independent-samples t-test, 
p > 0.05), the latter delivered a significantly higher amount of HEX H into the skin 
than the glycerol:DMI (50:50) solution (independent-samples t-test, p < 0.01). 
Although the DMI systems were not particularly effective in targeting HEX D and 
HEX H to the skin, differences were observed in the overall topical delivery of the 
two salts. Significantly higher amounts of HEX H were delivered into the skin from 
the PG:DMI and glycerol:DMI solutions (one-sample t-test, p < 0.01 and p < 0.05, 
respectively). However, no differences were found between the solution of HEX H in 
PEG 200:DMI and the saturated solution of HEX D in the same system 
(independent-samples t-test, p = 0.051). This last outcome was particularly 
interesting considering that HEX D had maximal thermodynamic activity in PEG 
200:DMI. It may be concluded that for this set of binary systems at least, the use of 
the dihydrochloride rather than the diisethionate salt is preferred for optimum 
delivery into the skin. 
The amounts of HEX D and HEX H extracted from the skin for the PG 
solutions were significantly higher than those for the corresponding PG:DMI (50:50) 
solutions (one-sample t-test, p < 0.001 and Mann-Whitney u-test, p < 0.01, 
respectively). The same was observed for the glycerol solutions which, again, 
delivered more of each active into the skin than the glycerol:DMI vehicle (one-
sample t-test, p < 0.001 and independent-samples t-test, p < 0.05, respectively). The 
topical delivery of HEX D from the PEG 200 solution was significantly higher than 
for the saturated solution of HEX D in PEG 200:DMI (independent-samples t-test, p 
< 0.05), no differences were found between the same solvent systems containing 
HEX H (independent-samples t-test, p > 0.05).Contrasting opinions on the efficacy 
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of DMI as a CPE are reported and, in some studies, DMI has been used as a control 
or diluent for other penetration enhancers because it was considered to have no 
enhancing action (Bennett et al., 1985; Funke et al., 2002).  
 
3.3.3. Binary systems of PG, glycerol and PEG 200 with 1,2-PENT 
No HEX D penetrated through the skin from the PG:1,2-PENT, glycerol:1,2-
PENT and PEG 200:1,2-PENT vehicles (Table 1). All three systems delivered ~ 1% 
of the applied HEX D dose into the skin. As a result, the skin extraction recoveries 
were statistically lower than the corresponding skin surface and total recoveries (one-
way ANOVA, p < 0.001). Amounts of HEX D recovered from the skin surface, are 
not significantly different from values for total recovery (one-way ANOVA, p > 
0.05). The three binary solvent systems delivered similar amounts of HEX D into 
skin (one-way ANOVA, p > 0.05).  
As for HEX D, no HEX H permeated from the PG:1,2-PENT, glycerol:1,2-
PENT and PEG 200:1,2-PENT solutions (Table 2). The majority of the HEX H was 
also found on the skin surface with most values >90% of the applied dose and these 
were not significantly different from the corresponding values for total recovery 
(one-way ANOVA, p > 0.05). The percentage of the applied HEX H recovered 
inside the skin ranged from 0.79% for the glycerol:1,2-PENT system to 1.14% for 
the PEG 200:1,2-PENT. As a result, all the extraction recoveries were statistically 
lower than the corresponding skin surface and total recoveries (one-way ANOVA, p 
< 0.001). Interestingly, as already seen for HEX D, no significant differences were 
observed between the amounts of HEX H that the three vehicles delivered into the 
skin (one-way ANOVA, p > 0.05).  
Overall, the topical delivery of HEX from the 1,2-PENT systems was not 
significantly affected by the choice of salt. The amounts of active extracted from the 
skin for the PG:1,2-PENT and PEG 200:1,2-PENT formulations of HEX D were not 
significantly different from those for the corresponding HEX H solutions (Mann-
Whitney u-test, p > 0.05 and independent-samples t-test, p > 0.05, respectively). In 
contrast, the glycerol:1,2-PENT solution delivered a statistically higher amount of 
HEX D into the skin than HEX H (independent-samples t-test, p < 0.05). The use of 
1,2-PENT as a CPE is relatively recent. There is little published data on the 
penetration enhancement properties of this solvent. Duracher et al. (2009) 
demonstrated the efficacy of 1,2-PENT for enhancement of delivery of the model 
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hydrophilic active, caffeine, in porcine ear skin, under finite dose conditions. The 
authors not only showed that 1,2-PENT was more efficient than PG, ethanol and 
water but also observed a concentration dependent effect of 1,2-PENT. In the present 
study the combination of 1,2-PENT with PG, glycerol and PEG 200 did not improve 
the topical delivery of HEX D and HEX H beyond that achieved with the single 
solvent systems. No significant differences were detected between the amounts of 
HEX D and HEX H delivered into the skin by neat glycerol  and the corresponding 
1,2-PENT binary systems (independent-samples t-test, p > 0.05). For PEG 200, no 
statistical differences were found between HEX D delivery from the neat solvent and 
in PEG 200:1,2-PENT (independent-samples t-test, p > 0.05). Similarly, PEG 200 
was more efficient than PEG 200:1,2-PENT in delivering HEX H (independent-
samples t-test, p < 0.05). In contrast, the PG:1,2-PENT vehicle did deliver a higher 
amount of HEX D into the skin than neat PG (independent-samples t-test, p < 0.05), 
however the opposite effect was observed for HEX H (Mann-Whitney u-test, p < 
0.05). 
 
3.3.4 Binary systems of PG, glycerol and PEG 200 with IPA 
No HEX D permeated from the PG:IPA, glycerol:IPA and PEG 200:IPA 
solutions (Table 1). Most of the applied HEX D was recovered from the skin surface 
(Table1). With the exception of the glycerol:IPA system, where skin surface and 
total recoveries were statistically different (one-way ANOVA, p < 0.05), no 
significant differences were found between the values for skin surface recovery and 
the corresponding values for total recovery of the other IPA binary solvent systems 
(one-way ANOVA, p > 0.05). All solutions delivered > 1.5% of the applied HEX D 
dose into the skin. The amount of HEX D recovered inside the skin ranged from 4.23 
± 1.48 µg for PEG 200:IPA to 8.48 ± 4.14 µg for PG:IPA but no significant 
differences were observed between the vehicles (one-way ANOVA, p > 0.05).  
No HEX H was found in the Franz cell receptor compartments for the PG:IPA, 
glycerol:IPA and PEG 200:IPA solutions (Table 2). More than 95% of the active was 
recovered from the skin surface while less than 1.5% was found inside the 
membrane. The skin extraction recoveries were thus significantly lower than the 
corresponding skin surface and total recoveries (one-way ANOVA, p < 0.001) 
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which, in turn, did not show statistical differences (one-way ANOVA, p > 0.05). All 
binary solvent systems delivered similar amounts of HEX H into the skin and no 
statistical differences were observed between them (one-way ANOVA, p > 0.05).  
Interestingly, the use of IPA in combination with PG or glycerol facilitated the 
topical delivery of hexamidine as the diisethionate rather than as the dihydrochloride 
salt. The PG:IPA and glycerol:IPA vehicles delivered significantly higher amounts of 
HEX D into the skin than the corresponding solutions of HEX H (independent-
samples t-test, p < 0.05). No statistical differences were found between the amounts 
of HEX D and HEX H extracted from the skin for the PEG 200:IPA solutions 
(independent-samples t-test, p > 0.05). The addition of IPA to PG, glycerol or PEG 
200 was also effective in enhancing the topical delivery of HEX D compared with 
the effects of the neat vehicles, while no effect was observed for HEX H. The 
PG:IPA, glycerol:IPA and PEG 200:IPA vehicles delivered statistically higher 
amounts of HEX D into the skin than PG, glycerol and PEG 200 alone (independent-
samples t-test, p < 0.05, p < 0.01 and p < 0.05, respectively). In contrast, no 
significant differences were found between the amounts of HEX H extracted from 
the skin for the neat PG and glycerol solutions and the related binary systems with 
IPA (independent-samples t-test, p > 0.05). In addition, the topical delivery of HEX 
H from PEG 200 was significantly higher than that from PEG 200 in combination 
with IPA (independent-samples t-test, p < 0.05). IPA is widely used in dermal and 
transdermal products because of its established penetration enhancing activity (Lane, 
2013) but clearly it is ineffective here when combined with PEG 200 for HEX H.  
 
3.3.5 Binary systems of PG, glycerol and PEG 200 with PGML 
The respective values for saturation solubility of HEX D at 32°C in the 
PG:PGML, glycerol:PGML and PEG 200:PGML vehicles were determined to be 
0.44±0.02, 0.46± 0.03 and 0.36±0.02 mg/mL (n=3). The permeation profile of HEX 
D from a saturated solution in PG:PGML is shown in Figure 2. No permeation was 
observed for the saturated solutions of HEX D in glycerol:PGML and PEG 
200:PGML. 
 
P a g e | 20  
 
 
 
 
 
HEX D was detected in the Franz cell receptor compartment 24 h after the 
application of a saturated solution in PG:PGML. Although initially the active 
permeated at a constant rate, the flux decreased after 32 h and the permeation profile 
reached a plateau. Mass balance studies indicated that 34.06% of the applied HEX D 
dose was found on the skin surface (Figure 3). It is possible that the decrease of HEX 
D flux reflects depletion of the active itself from the donor solution. The low plateau 
value may also indicate stranding of the active or crystallization in skin (Hadgraft 
and Lane, 2016). Finally, despite the high variability observed, the amounts of HEX 
D permeated were statistically different from zero at all time points (one-sample t-
test, p < 0.05). 
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Figure 2 Cumulative amount of HEX D permeated over 48 h from a saturated solution in 
PG:PGML (n=5; mean ± SD) 
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Figure 3 shows that all the binary solvent systems delivered just over 25% of 
the applied HEX D into the skin. For the PG:PGML system, the skin surface and the 
skin extraction recovery values were not statistically different (one-way ANOVA, p 
> 0.05) but were both significantly higher than the amounts which permeated 
through the skin (one-way ANOVA, p < 0.01). The results for the glycerol:PGML 
and the PEG 200:PGML systems contrast with those for PG:PGML, primarily  
because the respective skin surface recoveries were significantly higher than the skin 
extraction values (one-way ANOVA, p < 0.05). Nonetheless, the values are still 
significantly lower than corresponding total amounts recovered (one-way ANOVA, p 
< 0.01 and p < 0.05, respectively). The topical delivery of HEX D ranged from 23.05 
± 7.67 µg for PEG 200:PGML to 30.02 ± 11.25 µg for glycerol:PGML, however, no 
statistical differences were observed between the three binary solvent systems (one-
way ANOVA, p > 0.05). Finally, the total recovery values for all vehicles were 
below the accepted range of 80 – 120% (OECD, 2011).. As HEX D was previously 
34.06 27.02
3.44
64.52
46.84
25.99
ND
72.82
49.96
25.89
ND
75.85
Skin Surface Skin Extraction Skin Permeation Total
0
10
20
30
40
50
60
70
80
90
100
R
ec
o
v
er
y
 (
%
)
 HEX D saturated PG:PGML (50:50)
 HEX D saturated Glycerol:PGML (50:50)
 HEX D saturated PEG 200:PGML (50:50)
Amount Extracted (µg)
29.85 ± 11.32 30.02 ± 11.25 23.05 ± 7.67
Amount Permeated (µg)
3.80 ± 0.54 ND ND
 
Figure 3 Percentage of HEX D on skin surface, extracted from skin, permeation at 48 h and 
total recovery for saturated PG:PGML, glycerol:PGML and PEG 200:PGML solutions. 
Actual amounts of active recovered by extraction and measured in receptor compartment also 
inset (n=5; mean ± SD) 
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found to be stable in both PG:PGML and PBS (Parisi et al., 2015), the low total 
recovery might be attributed to interaction and/or degradation by skin enzymes. 
For HEX H, no permeation was observed for PG:PGML, glycerol:PGML and 
PEG 200:PGML. Results for the mass balance evaluation are shown in Figure 4.  
 
 
 
 
 
 
The PG:PGML solution delivered 74.24% of HEX H into the skin. This value 
was significantly higher than the percentage of HEX H found on the skin surface 
(one-way ANOVA, p < 0.001) and also not statistically different from the total 
recovery (one-way ANOVA, p > 0.05) which, in turn, was significantly higher than 
the skin surface recovery value (one-way ANOVA, p < 0.001). Contrasting results 
were observed for the glycerol:PGML and the PEG 200:PGMLsolutions. Their skin 
extraction recovery values were significantly lower than the corresponding skin 
surface and total recovery values (one-way ANOVA, p < 0.001). Lastly, the 
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percentages of HEX H recovered on the skin surface for the glycerol:PGML and the 
PEG 200:PGML solutions were statistically lower than the corresponding total 
recoveries (one-way ANOVA, p < 0.05 and p < 0.01, respectively). The 
glycerol:PGML and PEG 200:PGML solutions delivered similar amounts of HEX H 
into the skin (20.5 ± 8.2 µg and 27.4 ± 12.4 µg, respectively) with no significant 
differences between these values (one-way ANOVA, p > 0.05). The PG:PGML 
system, however, clearly impacted favourably on topical delivery of HEX H, with 
significantly higher amounts delivered to skin (181.0 ± 35.3 µg) compared with the 
other two vehicles (one-way ANOVA, p < 0.001). Total recovery of HEX H was 
within the accepted range for the PG:PGML vehicle but below the lower limit for the 
PEG 200:PGML and glycerol:PGML systems. HEX H was previously found to be 
stable in PBS and PEG 200 (Parisi et al., 2015) but no stability studies were 
performed in binary mixtures of PEG 200 with PGML or glycerol with PGML. 
Therefore values for the total recovery of HEX H may reflect stability issues in these 
solvent combinations and/or skin metabolism as already hypothesised for HEX D. 
While HEX H was used at a concentration of 0.1% w/v, saturated solutions of 
HEX D were prepared in all three PGML systems studied. As a result, HEX D is at 
its maximal thermodynamic activity and higher skin penetration might be expected 
for these solutions. Surprisingly, no statistical differences were found between the 
amounts of HEX D extracted from the skin for glycerol:PGML and PEG 200:PGML 
and the corresponding amounts of HEX H for the same vehicles (independent-
samples t-test, p > 0.05). Moreover, the topical delivery of HEX H from PG:PGML 
was significantly higher than the combined amounts for HEX D in the skin and in the 
receptor compartment for the corresponding saturated system (independent-samples 
t-test, p < 0.001)., In contrast to HEX D, no HEX H was delivered across the skin 
from the PG:PGML solution and the active is thus truly targeted to the skin. Overall, 
it may be concluded that the use of the dihydrochloride salt of hexamidine versus the 
diisethionate form positively impacted the topical delivery of the active from the 
PGML binary solvent systems. 
The inclusion of PGML in the binary systems with PG, glycerol and PEG 200 
was clearly effective in enhancing the topical delivery of both HEX D and HEX H 
when compared with the neat solvents. The amounts of HEX D extracted from the 
skin following the application of saturated solutions in PG:PGML, glycerol:PGML 
and PEG 200:PGML were 17, 15 and 9 times higher than those obtained from the 
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corresponding solutions of HEX D in PG, glycerol and PEG 200 (independent-
samples t-test, p < 0.01). A 50-, 9- and 6-fold increase in the topical delivery of HEX 
H was obtained for the solutions in PG:PGML, glycerol:PGML and PEG 200:PGML 
in comparison to the single solvent systems (independent-samples t-test, p < 0.001, p 
< 0.05 and p < 0.05, respectively).  
PGML is the monoester of lauric acid with PG and is used in dermal and 
topical drug delivery as a water-in-oil surfactant, emulsion stabiliser and active 
ingredient solubiliser and is associated with enhanced penetration of actives 
(Gattefossé, 2010a; Gattefossé, 2010b). Neat PGML, incorporated into a silicone 
based pressure sensitive adhesive, enhanced estradiol permeation through human 
cadaver epidermis (Irion et al., 1995). PGML has also been combined with other 
vehicles and synergistic actions have been demonstrated. Roy et al. (1994), for 
instance, showed that the addition of 10% PGML to PG increased buprenorphine 
flux through human cadaver epidermis by a factor of 7.5 compared with PG alone. In 
the same study it was also demonstrated that the concomitant inclusion of 15% 
PGML and 5% water to PG led to a 110-fold increase in the transdermal transport of 
the hydrochloride salt of buprenorphine. The recent work of Mohammed et al. 
(2014) highlighted the exceptional effect of PG:PGML (50:50) on the delivery of 
niacinamide across human skin both in-vitro and in-vivo. In the in-vitro permeation 
studies, the niacinamide flux from the binary solvent system was 437 times higher 
than that from neat PG. The in-vivo confocal Raman spectroscopy studies showed 
that the signal intensity of the stratum corneum depth profile of niacinamide was 
considerably stronger for the PG:PGML system rather than for PG alone. The grade 
of PGML used in the present work is reported to contain less than 6% of free 
saturated fatty acids, the majority being lauric acid (Gattefossé, 2010b). Saturated 
fatty acids are well known chemical penetration enhancers and their maximal activity 
is associated with chain lengths of C9-C12 (Aungst et al., 1986; Aungst, 1989). A 
number of publications demonstrated both the efficacy of lauric acid and the impact 
of its synergy with PG on the transdermal deliveries of actives with disparate 
physicochemical properties using human skin (Green et al., 1988; Roy et al., 1994). 
Lauric acid has been shown to form ion pairs with cationic actives, thus increasing 
their hydrophobic nature and enhancing their transport through lipophilic membranes 
(Green and Hadgraft, 1987; Green et al., 1988; Stott et al., 2001). The presence of 
lauric acid may therefore have contributed to the enhancing effect of PGML on the 
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topical delivery of HEX D and HEX H. It is also notable that most of the literature 
has focused on the ability of PGML to enhance transdermal rather than topical 
delivery of actives. 
 
Conclusions 
As we have previously reported, the physicochemical properties of HEX H 
suggest that this salt is a better candidate for topical delivery than HEX D. Despite a 
higher melting point, HEX H has a smaller MW and a higher log Do/w at pH = 7.4 
than HEX D. It was thus expected that the various solvent systems evaluated should 
target HEX H to skin more effectively than HEX D. Overall the use of the 
dihydrochloride rather the diisethionate salt did not have a significant impact on the 
topical delivery of hexamidine. One possible reason for this may be that the 
increased lipophilicity obtained by the substitution of the isethionate anion with the 
hydrochloride was not sufficient to produce a marked improvement in penetration of 
the active through the skin barrier.  
 Only 10 of the 30 binary solvent systems delivered higher amounts of active 
into the skin than the corresponding single solvent systems. Interestingly, except for 
the PG:1,2-PENT solution of HEX D, none of these ten systems contained TC, DMI 
or 1,2-PENT. DMI did not promote the skin penetration of HEX D and HEX H and 
its binary systems with PG and glycerol were the only vehicles which did not deliver 
any HEX D inside the skin. The combination of 1,2-PENT with PG, glycerol and 
PEG 200 did not improve the topical delivery of HEX D and HEX H with the 
exception of the solution of HEX D in PG:1,2-PENT. For these particular binary 
systems it is reasonable to speculate that their poor performance reflected the 
favourable solubility of both HEX D and HEX H in 1,2-PENT (15.31 mg/mL and 
22.65 mg/mL, respectively). As a result, the thermodynamic activity of HEX D and 
HEX H in binary solvent systems containing 1,2-PENT is comparatively low thus 
affecting the driving force of the systems and, ultimately, reducing the partitioning of 
the actives into the stratum corneum. IPA is present in 3 of the 10 binary solvent 
systems which enhanced topical delivery compared with neat solvents; interestingly, 
while IPA promoted skin uptake of HEX D, no effect was observed for HEX H. 
The 6 binary solvent systems containing PGML in combination with PG, 
glycerol and PEG 200 complete the set of the ten systems which enhanced the topical 
delivery of HEX D and HEX H with the PG:PGML system clearly outranking the 
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other vehicles. As noted, neat PGML is reported to enhance the percutaneous 
penetration of several active ingredients and synergistic effects have been reported 
when PGML is combined with hydrophilic enhancers containing hydroxy groups 
such as PG. Glycerol, which has three hydroxy groups in its chemical structure, and 
PEG 200, which has two hydroxy groups and numerous ether groups, are hydrophilic 
solvents. It may thus be hypothesised that as for PG, the combination of glycerol and 
PEG 200 with PGML may exert a synergistic action on the skin delivery of active 
ingredients and, in this case, may have contributed to the enhancement of the topical 
delivery of HEX D and HEX H. The PGML grade used for these investigations 
contained small percentages of lauric acid which has enhancing effects in its own 
right and it also acts synergistically with PG. To determine whether an ion-pair 
mechanism is relevant for this work further experiments are ongoing.  
Finally, it is important to note that the mechanisms of action of the enhancers 
examined in this study remain to be fully elucidated. Even though we have 
conducted a comprehensive evaluation of two salts of the same active it is clearly not 
possible to predict that enhancement effects will be achieved depending on the CPEs 
selected. We believe this further underlines the necessity for fundamental 
investigations into the fate of excipients and CPEs when applied to the skin. These 
studies will provide important insights for rational formulation design in the future. 
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